GSK2636771 is a novel, potent, selective and orally bioavailable inhibitor of PI3Kβ (phosphatidylinositol 3-kinase β) with potential anticancer activity.

NU7441 (also called KU-57788) is a highly potent, selective and ATP-competitive inhibitor of DNA-PK (DNA-dependent protein kinase) with IC50 of 14 nM, has anticancer activity.

Omipalisib (also called GSK-2126458, GSK-458), a pyridylsulfonamide analog, is a potent, highly selective and orally bioavailable small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) p110α/β/δ/γ with potential anticancer activity.

SF2523 (SF-2523; SF 2523) is a novel, selective and potent dual inhibitor of PI3K-BRD4 with potential anticancer activities.

Duvelisib (formerly known as IPI-145 and INK1197, trade name: Copiktra), an isoquinolinone derivative, is a novel potent, orally bioactive and selective small-molecule phosphoinositide-3 kinases (PI3K) inhibitor with potential anticancer activity.

YM201636, a pyridofuropyrimidine compound, is a novel, potent and selective PIKfyve (phosphatidylinositol‑3‑phosphate 5‑kinase) inhibitor with potential anti-retroviral replication and anticancer activity, as silencing of PIKfyve which is the sole enzyme for PtdIns(3,5)P(2) biosynthesis that controls proper endosome dynamics, can inhibit retroviral replication.

Copanlisib HCl (formerly BAY-806946; BAY 80-6946; Aliqopa), the hydrochloride salt of Copanlisib, is a pan-class I PI3K (phosphoinositide 3-kinase) inhibitor approved in 2017 for the treatment of relapsed follicular lymphoma.